Swisscanto Private Equity

ANYbotics AG is a Swiss robotics company founded in 2016 and based in Zurich. The company specializes in developing autonomous legged robots designed for industrial applications, particularly in hazardous and complex environments. These robots feature advanced capabilities such as docking stations, robust waterproof designs, and various sensing technologies. They are equipped to perform tasks like asset monitoring, equipment health checks, and event detection, thereby enhancing productivity and safety for workers in sectors such as oil and gas, power, energy, mining, chemicals, transportation, and construction. With a team of over 100 employees, ANYbotics aims to support industrial facilities in their inspection needs, promoting more sustainable operations through intelligent robotic solutions.

ANYbotics AG is a Swiss robotics company founded in 2016 and based in Zurich. The company specializes in developing autonomous legged robots designed for industrial applications, particularly in hazardous and complex environments. These robots feature advanced capabilities such as docking stations, robust waterproof designs, and various sensing technologies. They are equipped to perform tasks like asset monitoring, equipment health checks, and event detection, thereby enhancing productivity and safety for workers in sectors such as oil and gas, power, energy, mining, chemicals, transportation, and construction. With a team of over 100 employees, ANYbotics aims to support industrial facilities in their inspection needs, promoting more sustainable operations through intelligent robotic solutions.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, the company is dedicated to addressing the unmet medical needs of patients globally. Its lead candidate, VS-01, is in the preclinical stage and aims to be the first drug for acute liver disease, with the unique capability of supporting multiple organ function. VS-01 has received Orphan Drug Designation for acute liver failure, highlighting its potential in treating rare conditions. Additionally, Versantis is advancing other products in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent significant opportunities for improving patient outcomes in the field of liver health and beyond.